Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Kymera Therapeutics Q1 EPS $(0.69) Beats $(0.73) Estimate, Sales $10.29M Miss $13.69M Estimate

Author: Benzinga Newsdesk | May 02, 2024 07:08am

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.73) by 5.48 percent. This is a 1.43 percent increase over losses of $(0.70) per share from the same period last year. The company reported quarterly sales of $10.29 million which missed the analyst consensus estimate of $13.69 million by 24.86 percent. This is a 8.67 percent increase over sales of $9.47 million the same period last year.

Posted In: KYMR